GlassScriptPhysician profile
Brian Charles Procter
NPI 1093780330
$10,149.42
in general payments reported to CMS, 2019-2025
55 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,023 · 2020: $1,893 · 2021: $2,138 · 2022: $1,359 · 2023: $1,545 · 2024: $762 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,675 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,675.23 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,275.50 | 2019-2024 | |
| Novo Nordisk INC | $1,237.71 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Allergan, INC. | $575.33 | 2019-2022 | |
| Pfizer INC. | $554.51 | 2019-2024 | |
| Corium, LLC | $419.00 | 2021-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $407.63 | 2019-2024 | Verquvo, Belsomra |
| Arbor Pharmaceuticals, INC. | $402.91 | 2019-2022 | |
| Amgen INC. | $340.33 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $320.87 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $319.36 | 2019-2025 | Airsupra, Farxiga |
| Antares Pharma, INC. | $298.53 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Lilly USA, LLC | $289.45 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $233.72 | 2019-2022 | |
| Corcept Therapeutics | $230.86 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $219.53 | 2019-2023 | Trintellix |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Procter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.